Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any inaccuracy or lack of information to info@ticinoscienza.ch

1) Targeting PML in triple negative breast cancer elicits growth suppression and senescence
Cell Death and Differentiation, aprile 2020

2) Esmethadone-HCl (REL-1017): a promising rapid antidepressant
European Archives of Psychiatry and Clinical Neuroscience, 8 marzo 2023

3) Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Cancer Cell, 22 febbraio 2023

4) REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial
The American Journal of Psychiatry, febbraio 2022

5) Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors: A way to reactivate the antitumor immunity
OncoImmunology, 22 gennaio 2015

6) Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer
Cell Reports, 28 aprile 2015

7) Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity
Cell Reports, 9 ottobre 2014

8) Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Nature, 6 novembre 2014

9) Marine sponge Cribrochalina vasculum compounds activate intrinsic apoptotic signaling and inhibit growth factor signaling cascades in non-small cell lung carcinoma
Molecular Cancer Therapeutics, dicembre 2014

10) CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression
Scientific Reports, 2 gennaio 2023

11) Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
International Journal of Molecular Sciences, 13 ottobre 2022

12) B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
European Urology, 13 settembre 2022

13) Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Pharmaceuticals, 13 agosto 2022

14) P1245 Polymorphic Variants of HSD3B1 Gene Confer Different Outcome in Specific Subgroups of Patients Infected With SARS-CoV-2
Frontiers in Medicine, 7 luglio 2022

15) Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer
Nature Communications, 21 aprile 2022

16) HER3 Is an Actionable Target in Advanced Prostate Cancer
Cancer Research, 15 dicembre 2021

17) Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
Science, 8 ottobre 2021

18) CD38 in Advanced Prostate Cancers
European Urology, 1 marzo 2021

19) Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Nature Communications, 2 febbraio 2021

20) Genetic and hormonal influence on SARS-CoV-2-infection susceptibility: Re: The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence and mortality
Annals of Oncology, novembre 2020

21) Reply to the Letter to the Editor "Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients" by N. Bennani and I. M. Bennani-Baiti
Annals of Oncology, novembre 2020

22) Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis
Cancer Cell, 26 ottobre 2020

23) In and out from senescence
Nature Cell Biology, 26 giugno 2020

24) Prostate Carcinogenesis: Inflammatory Storms
Nature Reviews Cancer, https://www.nature.com/articles/s41568-020-0267-9

25) CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
The Journal of Clinical Investigation, https://www.jci.org/articles/view/131133
Andrea Alimonti
is currently collaborating with
Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5
6500 Bellinzona
Andrea Alimonti
on behalf of Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Molecular Oncology
as Group Leader